[go: up one dir, main page]

AU2002237717A1 - Method for modulation, stimulation, and inhibition of glutamate reuptake - Google Patents

Method for modulation, stimulation, and inhibition of glutamate reuptake

Info

Publication number
AU2002237717A1
AU2002237717A1 AU2002237717A AU3771702A AU2002237717A1 AU 2002237717 A1 AU2002237717 A1 AU 2002237717A1 AU 2002237717 A AU2002237717 A AU 2002237717A AU 3771702 A AU3771702 A AU 3771702A AU 2002237717 A1 AU2002237717 A1 AU 2002237717A1
Authority
AU
Australia
Prior art keywords
alkyl
glutamate
transporter
compounds
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002237717A
Other languages
English (en)
Inventor
Maria-Luisa Maccecchini
Xue-Feng Pei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annovis Inc
Original Assignee
Annovis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annovis Inc filed Critical Annovis Inc
Publication of AU2002237717A1 publication Critical patent/AU2002237717A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002237717A 2000-10-30 2001-10-30 Method for modulation, stimulation, and inhibition of glutamate reuptake Abandoned AU2002237717A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24425200P 2000-10-30 2000-10-30
US60244252 2000-10-30
PCT/US2001/048448 WO2002040002A2 (fr) 2000-10-30 2001-10-30 Procede de modulation, de stimulation et d'inhibition de la reabsorption du glutamate

Publications (1)

Publication Number Publication Date
AU2002237717A1 true AU2002237717A1 (en) 2002-05-27

Family

ID=22921993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002237717A Abandoned AU2002237717A1 (en) 2000-10-30 2001-10-30 Method for modulation, stimulation, and inhibition of glutamate reuptake

Country Status (5)

Country Link
US (1) US20020188022A1 (fr)
EP (1) EP1365758A2 (fr)
AU (1) AU2002237717A1 (fr)
CA (1) CA2427819A1 (fr)
WO (1) WO2002040002A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182549A1 (fr) * 2017-05-11 2019-09-26 Richard Postrel Procédés primaires et processus de prolongement de durée de vie chez des êtres humains de jour moderne
CN109111391A (zh) * 2018-07-03 2019-01-01 杭州师范大学 一种含三元环骨架的手性吡咯烷衍生物及其合成方法与应用
RU2767532C1 (ru) * 2021-05-27 2022-03-17 Общество с ограниченной ответственностью "ТЕРРАНОВА КАПИТАЛ" Пептид, обладающий бронхопротекторным действием, фармацевтическая композиция на его основе и способ ее применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68912822T2 (de) * 1988-05-16 1994-06-09 Searle & Co 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen.
DE69614835T2 (de) * 1995-02-15 2002-04-25 Annovis, Inc. Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
EP0913389A4 (fr) * 1996-06-28 2000-02-02 Nippon Chemiphar Co Derives de cyclopropylglycine et agoniste du recepteur du l-glutamate du type a regulation metabolique
JP2002513405A (ja) * 1997-02-28 2002-05-08 ベアーズデン バイオ，インコーポレイテッド コンピューターモデリングによるタンパク質−リガンド相互作用の決定方法
CA2318800C (fr) * 1998-01-28 2005-12-20 Taisho Pharmaceutical Co., Ltd. Derives d'acides amines renfermant du fluor
CA2282236A1 (fr) * 1998-11-06 2000-05-06 Peter Stys L'utilisation des acides aminés transporteurs inhibiteurs pour prévenir des blessures a la substance blanche du snc

Also Published As

Publication number Publication date
WO2002040002A2 (fr) 2002-05-23
EP1365758A2 (fr) 2003-12-03
US20020188022A1 (en) 2002-12-12
WO2002040002A3 (fr) 2003-08-21
CA2427819A1 (fr) 2002-05-23

Similar Documents

Publication Publication Date Title
Rousseaux et al. Sigma receptors [σ Rs]: biology in normal and diseased states
Williams et al. Modulation of the NMDA receptor by polyamines
Uzbay et al. Effects of agmatine on ethanol withdrawal syndrome in rats
US6512009B1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
TW200812568A (en) Pharmaceutical composition with synergistic anticonvulsant effect
Montiel et al. Differential effects of the substrate inhibitor L-trans-pyrrolidine-2, 4-dicarboxylate (PDC) and the non-substrate inhibitor DL-threo-β-benzyloxyaspartate (DL-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo
Quartaroli et al. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A
Campiani et al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases
US20020115688A1 (en) Screen for glutamate reuptake inhibitors, stimulators, and modulators
WO2003024443A1 (fr) Matieres et methodes de traitement de troubles neurologiques consistant a suractiver les recepteurs inotropiques glutamatergiques
Aricioglu et al. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system
US20240122897A1 (en) Dmt salts and their use to treat brain injury
FI105025B (fi) Menetelmä valmistaa (S)-alfa-fenyyli-2-pyridiinietaaniamiinia
US20020188022A1 (en) Methods for modulation, stimulation, and inhibition of glutamate reuptake
JP3925712B2 (ja) 興奮性侵襲に対するニューロンの保護が可能なｎ−アルキルグリシン三量体および該三量体を含有する組成物
Kudo et al. A significant increase in intracellular Ca2+ concentration induced by (2S, 3R, 4S)-2-(car☐ ycyclopropyl) glycine, a new potent NMDA agonist, in cultured rat hippocampal neurons
Higgins et al. Bicuculline‐resistant paired‐pulse inhibition in the rat hippocampal slice
US20040033958A1 (en) N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
JP3023987B2 (ja) （Ｓ）−α−フェニル−２−ピリジンエタンアミン（Ｓ）−マレートおよび医薬としてのその使用
Jaffe et al. Glutamate receptor desensitization block potentiates the stimulated GABA release through external Ca2+-independent mechanisms from granule cells of olfactory bulb
JPH05170668A (ja) パーキンソン症候群を治療するための薬剤学的製剤
US20070142467A1 (en) 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission
US20020115721A1 (en) Esters of alkycarboxy amino acids as prodrugs of modulators of the kainate receptor
US7432296B2 (en) Pharmaceutical formulations containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
Meller et al. The role of nitric oxide in hyperalgesia